Envision Pharma Group appoints Head of Envision Value & Access

Envision Pharma Group is pleased to announce the appointment of Mel Formica as its Head of Envision Value & Access.

Envision Pharma Group appoints Head of Envision Value & Access

Oct 03, 2022
Envision Pharma Group appoints Head of Envision Value & Access Image

Mel is a highly respected international life science leader with proven P&L and operational leadership experience, as well as private equity advisory expertise. As an innovator in developing distinctive market entry and commercial strategies that combine customer insight, vision, and creativity, Mel’s work is focused on the forefront of transformations in disruptive technologies, patient-level data, and improved quality of care.

Joining and strengthening an experienced Executive Leadership Team (ELT) at Envision, Mel will drive the growth and expansion of the Value & Access group, pursue service solution innovations, and spearhead the introduction of digital and data analytical capabilities that create impact and deliver value to life science clients.

Meg Heim, Envision’s Chief Executive Officer, said of Mel’s appointment, “Mel’s skillset and experience in industry and consulting aligns closely with our group strategy. His appointment comes at a point where our performance is accelerating and where we continue to drive forward, at pace, in delivering for clients in key strategic areas such as data and digital transformation. I am excited about the innovation, impact, and value he will bring to the talented teams here at Envision, and to our life science clients.”

Mel added, “I am thrilled to be joining Envision at such an exciting time for the group. With a new CEO, ambitions for significant growth, and a drive for greater value and access service and technology integrations, I can’t think of a better time to be joining, supporting the ELT, and advancing the group strategy.”

Close

Please support the Medical Affairs Professional Society (MAPS) survey and competition

Envision is Number 1 in Sussex for the second year running

Envision Pharma Group’s Joseph Kohles joins the Medical Affairs Professional Society (MAPS) Executive Leadership Committee

Please support the Medical Affairs Professional Society (MAPS) survey and competition

Nov 09, 2017
Please support the Medical Affairs Professional Society (MAPS) survey and competition Image

Envision Pharma Group is delighted to continue to support the important work of the Medical Affairs Professional Society (MAPS) in furthering the aims of the Medical Affairs (MA) community.

MAPS is collecting feedback on MA professional development around medical leadership, data generation/distribution, and insights, to help inform how the society can best support the MA community. If you would like to participate in their short survey, the findings of which will be presented at the MAPS 2018 annual meeting in Miami, please follow the link below.

Please note Envision is not associated with the survey and will not see any results other than the aggregated responses presented at the annual meeting.

The survey can be found here:

Click here to take a brief survey and help us as we shape our future, together

As an appreciation for taking the time to complete the survey, MAPS will automatically enter survey respondents into a raffle for a chance to win one of two great prizes: a complimentary conference registration for their premier event, the MAPS 2018 Annual Meeting, taking place February 25-27 in Miami; or a free, one-year premium membership in MAPS with access to their soon-to-launch Medical Affairs Network.

Posted on behalf of Kirk V Shepard, MD, President 2016-2017, Medical Affairs Professional Society.

Further information on MAPS can be obtained from: http://www.medicalaffairs.org/

Close

Envision is Number 1 in Sussex for the second year running

Oct 25, 2017
Envision is Number 1 in Sussex for the second year running Image

Envision Pharma Group is delighted to be recognised as the top performing mid-market company and one of the Top 20 fastest-growing businesses in Sussex, having achieved sustained sales growth over the last three years.

Accountancy and business advisory firm BDO LLP’s most recent Best in Business research on the mid-market – which included companies with a turnover of between £10 and £300 million – has revealed Envision Pharma Group to be a real success story in Sussex.

This latest accreditation also shows Envision occupying the number one position in Sussex for the second year running, with a compound annual growth rate of 52% in revenues. BDO’s findings highlight the ongoing importance of such companies to the local economy.

Kevin Cook, Partner at BDO Guildford, commented: “Mid-market companies continue to drive growth in Sussex despite uncertainty caused by the Brexit negotiations. Envision Pharma Group is a great example of a business that, led by a strong management team, continues to embrace market opportunities and is well positioned to take advantage of any opportunities the changing economic landscape presents. We have a tremendous base of entrepreneurial and aspirational companies to be proud of locally.”

Envision Pharma Group’s Chief Strategy Officer, David Thompson, added: “Our efforts to augment the company's position as the leading scientific and technology company in the pharmaceutical services industry to a fully-fledged strategic multichannel partner for our medical affairs clients is starting to gain significant traction. This, in turn, is leading to further opportunities for both our talented staff and to new individuals joining the organisation. It’s a very exciting time.”

Click here to download the Best in Business Surrey and Sussex 2017/18 Report from the BDO Website.

Click here to read the article on the BDO Website.

Close

Envision Pharma Group’s Joseph Kohles joins the Medical Affairs Professional Society (MAPS) Executive Leadership Committee

Oct 24, 2017
Envision Pharma Group’s Joseph Kohles joins the Medical Affairs Professional Society (MAPS) Executive Leadership Committee Image

The Envision Pharma Group’s Chief Medical Officer Dr. Joseph Kohles has joined the Executive Leadership Committee for the Medical Affairs Professional Society (MAPS).

MAPS is the premier non-profit global society of Medical Affairs professionals across a spectrum of fields, experience, and locations. Joe’s appointment to the Committee will support the society as it transforms the Medical Affairs industry and increases its value to companies and, ultimately, benefits patients and consumers.

Speaking about MAPS, Joe said, “MAPS serves a critical need in the industry by uniting medical affairs professionals to share best practices, functional education, and generally promoting the value of the med affairs unit”.

Joe has been instrumental towards driving Envision’s strategic direction since joining the Group 2 years ago, and has more than 20 years of research and industry-side pharmaceutical experience, both in medical affairs and clinical research.

His previous industry experience included leading the oncology medical affairs team for a large Fortune 100 pharmaceutical company in the USA. In this capacity, he guided the overall medical strategy and led the team in execution of clinical trials, data analyses, publications plans, and overall medical support.

Joe has a broad range of experience across multiple therapeutic areas including oncology, osteoporosis, pain and diabetes, and he has written and published more than 20 peer-reviewed manuscripts and over 60 abstracts and posters spanning basic research, preclinical, clinical, health outcomes, and pharmaco-economic analysis.

MAPS has a mission to advance the Medical Affairs profession and increase its impact across the Life Sciences industry by promoting excellence across Medical Affairs functions; developing guidelines to support industry standards and best practices; fostering advocacy for Medical Affairs position; and providing education and encouraging professional collaborations that support the practice of Medical Affairs.

With a non-profit status, MAPS is able to reinvest all revenue back into the society, which gives it the ability to create valuable programs and resources that support the Medical Affairs community.

To find out more about MAPS or to become a member, click the below link:

http://www.medicalaffairs.org

Close

Our growing presence in Japan and the Asia-Pacific region

Dr Rebecca Lew, PhD, CMPP, of ProScribe, part of the Envision Pharma Group delivered the “Best of ISMPP” session at the recent ISMPP Country Champions Meetings in Tokyo on November 21 and in Singapore on November 25

Envision Pharma Group wins “Best Original Research” prize at ISMPP for the second year running

For the second year running, Envision Pharma Group has won the Best Original Research prize at the Annual Meeting of the International Society for Medical Publication Professionals (ISMPP)

Envision Receives ISO/IEC 27001 Certification

Our growing presence in Japan and the Asia-Pacific region

Aug 30, 2017
Our growing presence in Japan and the Asia-Pacific region Image

Dr Rebecca Lew, PhD, CMPP, of ProScribe, part of the Envision Pharma Group delivered the “Best of ISMPP” session at the recent ISMPP Country Champions Meetings in Tokyo on November 21 and in Singapore on November 25.  These meetings were a mixture of presentations and roundtable discussions designed to increase the awareness of the Good Publications Practice Guidelines (GPP3) in the Asia Pacific region and the practicalities of their implementation – a full agenda of the topics covered is available here.

Dr Lew’s presentation summarized the key takeaways from the 2016 ISMPP Annual Meeting and customized them for the Asia Pacific region. The Country Champion events bridge the information gap between the inaugural Asia Pacific Meeting of ISMPP in 2015 and the next iteration of this biennial meeting (Tokyo, September 5, 2017).

As awareness of GPP3 grows in the Asia-Pacific region, the need for compliant, technology-enabled, medical writing support is increasing. Consequently, Envision is delighted to announce that the ProScribe leadership team, Professor Karen Woolley, PhD, CMPP, and Mark Woolley, PhD, will be relocating to Tokyo to drive the expansion of our Japan team and enhance the range of services we provide in the region. Professor Karen Woolley is a renowned expert in the delivery of compliant publication programs, particularly in the Asia Pacific region, and is an author on the GPP3 Guidelines published in the Annals of Internal Medicine. A translation of this publication is now available in Chinese, with a Japanese translation coming soon.

In the near future, we will be bolstering our current writing and client solutions team in the Tokyo office with Japanese-language customer care support for Datavision® and our other technology solutions.

Datavision® is the industry-standard, purpose-built publication-planning software solution, developed and maintained by The Envision Pharma Group for the management of global publication plans. It is currently used by more than 60 pharma and medical device companies to ensure consistent operating practices across international boundaries. Datavision® manages the various publication-related activities of more than 35,000 registered users across these global clients, their affiliates, their supporting agencies and external authors.

Please visit our website for more information on our full range of Medical Affairs services, our industry-leading software solutions, including Datavision®, Visiontracker®, Visiontracker HEORTM, MedinfoTM, Clear®, and LibraryTM.

Close

Envision Pharma Group wins “Best Original Research” prize at ISMPP for the second year running

Aug 26, 2017
Envision Pharma Group wins “Best Original Research” prize at ISMPP for the second year running Image

For the second year running, Envision Pharma Group has won the Best Original Research prize at the Annual Meeting of the International Society for Medical Publication Professionals (ISMPP). ‘Development and reporting of research reporting guidelines — who and what are missing?’, conducted by Dr Serina Stretton, Dr Lauri Arnstein, and Professor Karen Woolley, was presented at the Annual Meeting of ISMPP, May 1-3, National Harbor, Maryland, USA.

This year’s success follows on from winning the Best Original Research Prize at last year’s ISMPP meeting. The ‘Forewarned is forearmed: Trends in industry-sponsored clinical trials relevant to publication professionals’ research was conducted by Dr Michelle Anderson, Masayo Hisayama, Dr Jessica Deckman, Dr Cassandra Haley, and Professor Karen Woolley.

Similar to the global nature of the medical communications profession, these research projects involved an international and multi-disciplinary research team of Envision employees from the US, UK, Japan, and Australia and, as may be expected at a leading medical communications conference, Envision’s presentations included augmented reality features, such as video clips, animated graphics, and Japanese audio translations.

Karen Woolley commented, “Research is not easy, but research is needed to inform, guide, and, is some cases, defend our profession. We want to thank ISMPP for providing members with a forum for sharing research results. We’re also humbled and delighted that our peers have recognized the quality and relevance of our research. To win the ‘Best Original Research’ prize for the second year in a row is a credit to the curiosity, ingenuity, and effort of our scientific teams. Importantly, our creative and editorial teams always ensure we can share our results with ISMPP attendees in visually appealing and interactive ways. The best research is always a team effort!”

Successive wins provide independent endorsement of Envision’s thought-leadership position in the industry. Envision staff have to know the field to ask relevant questions and the answers help Envision’s clients and the broader medical communications profession.

Close

Envision Receives ISO/IEC 27001 Certification

May 01, 2017
Envision Receives ISO/IEC 27001 Certification Image

Envision Pharma Group offices have successfully obtained certification to International Standard Organization (ISO)/IEC 27001.

ISO 27001 is the international standard for cyber security. By attaining this certification, Envision have demonstrated a clear commitment to Information Security Management to third-parties and stakeholders, providing a process and framework to ensure the fulfilment of commercial, contractual and legal responsibilities, and providing for a common security approach within the Envision business units and a formal basis for inter-operability between Envision and its customers.


ISO Certification is obtained only after a rigorous external audit process and our global locations comprising Horsham in the UK, Southport, Glastonbury, Madison, Philadelphia in the US along with Sydney in Australia are now ISOQAR Registered and carry the Certificate Number 14800.

Envision is committed to the policy for the ongoing development and continual improvement of our information security management systems, therefore, meeting the strict requirements of ISO 27001.

Our Information Security Policy applies to all Envision systems and information, and is one of our key values as an organisation – trust. Envision adheres to the highest ethical standards, we keep our promises and we aspire to create open, honest working relationships.

ISO develops standards, accepted as preeminent in over 140 countries including the USA, Australia, Japan and the UK. These standards facilitate international exchange of goods and services, support sustainable and equitable economic growth, promote innovation and protect health, safety and the environment.

Close

Envision Pharma Group announces the availability of Scopus citation counts in Datavision

Envision Pharma Group (“Envision”), a leading Medical Affairs-focused scientific communications and technology solutions provider, is pleased to announce that Datavision − the industry-leading software solution for strategic publication planning – will now feature citation counts provided by Scopus

Envision announces Altmetric attention data now available in Library™ scientific content management software

Envision Pharma Group (“Envision”), a leading Medical Affairs-focused scientific communications and technology solutions provider, announced today that Library – Envision’s searchable content management system for Medical Affairs materials, including publications and multimedia – will now feature attention data provided by data science company Altmetric

Envision Pharma Group launches Medinfo™ – a new purpose-built software solution for medical information

Envision Pharma Group (“Envision”), a leading Medical Affairs-focused scientific communications and technology solutions provider, is pleased to announce the launch of Medinfo™

Envision Pharma Group announces the availability of Scopus citation counts in Datavision

Apr 24, 2017
Envision Pharma Group announces the availability of Scopus citation counts in Datavision Image

Datavision® facilitates the compliant and transparent management of publication planning and delivery; the automated capture of various internal metrics (eg, time to submission, review times, approval times) allows the identification of inefficiencies and the optimization of the publication development process.

However, assessment of the ‘effectiveness’ or ‘impact’ of a publication often relies on the use of external metrics; a traditional measure of impact of a publication is the volume of citations in peer-reviewed literature. Envision has partnered with Scopus, a trusted provider of citation data, to ensure that Datavision records do not end at publication and that citation counts can be available for all publications tracked within the system.

Citation counts will be available to all Datavision users, with full details of the citing articles available via click-through to the Scopus system (available using an active Scopus subscription).

Russell Traynor, Envision’s Platform Director for iEnvision and former chair of the International Society of Medical Publication Professionals noted: “Citation metrics provide an invaluable benchmark for assessing the value and rigor of a piece of research. We are excited to be partnering with Scopus, as a leading provider of citation data, to bring this benchmarking ability to our global community of Datavision users.”

Russell added: “We are excited by this collaboration and hope that the addition of citations as an external measure of ‘impact’ will allow better assessment and optimization of the effectiveness of publication programs.”

For further information, please contact: Synnove Smeets (Synnove.Smeets@EnvisionPharmaGroup.com) or Russell Traynor (Russell.Traynor@EnvisionPharmaGroup.com).

About Envision

Founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies.

Envision is a leading provider of evidence communication services and industry-leading, technology solutions that have applicability across areas of Medical Affairs responsibility.

Under consistent leadership, Envision has grown steadily across its three core business areas in support of Medical Affairs:

Evidence Communication—including strategic publication planning, data dissemination services, medical education, and Market Access communications;

Technology Solutions—design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including: publication planning and management (Datavision), clearance and approval (Clear®), activity request and evidence generation management (Visiontracker®), workflow management for Health Economics and Outcomes Research activities (Visiontracker HEOR™), workflow management for Early Access Program activities (Visiontracker EAP™), searchable repository for the appropriate sharing of scientific content (Library™), and a next-generation solution for managing medical information enquiries (Medinfo™); and

Operational Excellence—policy, process, and compliance support and consultancy for Medical Affairs.

Envision has twelve offices: four in the United Kingdom – Horsham, Wilmslow, Marlow, and London; six in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT, and New York, NY; and two in the Asia-Pacific region – Tokyo and Sydney. The company employs 550 team members, including more than 200 highly qualified and experienced in-house medical writers and more than 100 technology solutions team members who provide software development and customer support. Envision provides services and technology solutions to more than 75 companies, including 19 of the top 20 pharmaceutical companies.

About Scopus

Launched in 2004 by Elsevier, Scopus is used by thousands of academic, government and corporate organizations to detect trends, find partnerships and identify experts to stay on the cutting edge of research. Combining the world’s largest abstract and citation database of peer-reviewed literature with smart tools to track, analyze and visualize research, Scopus is the tool to use if you need to keep track of global science.

Subscription pricing for Scopus varies according to the size of your organization. For more information about Scopus and subscription options, visit https://www.elsevier.com/solutions/scopus

Close

Envision announces Altmetric attention data now available in Library™ scientific content management software

Apr 24, 2017
Envision announces Altmetric attention data now available in Library™ scientific content management software Image

The ‘impact’ of a peer-reviewed publication is an integral part of the assessment of the effectiveness of an individual publication or cumulatively, of a publication plan. While citations have long been considered the standard measure of publication impact, they may on occasions take months or years to emerge.

The shift to an online publication environment and the rise of social media have allowed the real-time assessment of indicators of dissemination (eg, via Twitter), interest (eg, news coverage), and readership (eg, Mendeley). Envision has partnered with Altmetric, the leading provider of such metrics, to facilitate access to these informative data via the Library content management solution – part of the expanding iEnvision suite of medical project management software solutions.

Fully integrated into the publication details held within Library, Altmetric badges and associated attention scores provide constantly updated, at-a-glance indicators of the engagement relating to published articles, and permit click-through-access to the Altmetric.com website for more detailed information on the demographic, geographic, and contextual nature of these data please see Altmetric links below.

Library is built on the iEnvision™ Medical Project Management platform, purpose-built to meet the needs of Medical Affairs and related functions. Library can be fully integrated with current versions of Datavision® (publications management), as well as other third-party and corporate applications.

Russell Traynor, Envision’s Platform Director for iEnvision and former chair of the International Society of Medical Publication Professionals noted: “We are excited to announce this collaboration and hope that the addition of Altmetric data to Library will provide additional insights and value to the users of our solutions.”

Catherine Williams, Chief Marketing Officer, of Altmetric commented: “We’re really pleased to see Envision integrating our data and badges into the Library platform. The attention insights provided will be useful for pharmaceutical companies and communications agencies in assessing the performance of their own publications as well as those of their competitors, and will be a powerful tool for more informed strategic planning.”

For further information, please contact: Synnove Smeets (Synnove.Smeets@EnvisionPharmaGroup.com) or Russell Traynor (Russell.Traynor@EnvisionPharmaGroup.com).

Follow us on Twitter – @EnvisionPharma – or LinkedIn for company updates


About Envision

Founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies.

Envision is a leading provider of evidence communication services and industry-leading, technology solutions that have applicability across areas of Medical Affairs responsibility.

Under consistent leadership, Envision has grown steadily across its three core business areas in support of Medical Affairs:

Evidence Communication—including strategic publication planning, data dissemination services, medical education, and Market Access communications;

Technology Solutions—design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including: publication planning and management (Datavision®), clearance and approval (Clear®), activity request and evidence generation management (Visiontracker®), workflow management for Health Economics and Outcomes Research activities (Visiontracker HEOR™), workflow management for Early Access Program activities (Visiontracker EAP™), searchable repository for the appropriate sharing of scientific content (Library™), and a next-generation solution for managing medical information enquiries (Medinfo™); and;

Operational Excellence—policy, process, and compliance support and consultancy for Medical Affairs.

Envision has twelve offices: four in the United Kingdom – Horsham, Wilmslow, Marlow, and London; six in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT, and New York, NY; and two in the Asia-Pacific region – Tokyo and Sydney. The company employs 550 team members, including more than 200 highly qualified and experienced in-house medical writers and more than 100 technology solutions team members who provide software development and customer support. Envision provides services and technology solutions to more than 75 companies, including 19 of the top 20 pharmaceutical companies.


About Altmetric

Altmetric was founded in 2011 and has made it a mission to track and analyze the online activity around scholarly literature. It collates what people are saying about published research outputs in sources such as the mainstream media, policy documents, social networks, blogs, and other scholarly and non-scholarly forums to provide a more robust picture of the influence and reach of scholarly work. Altmetric works with some of the biggest publishers, funders, and institutions around the world to deliver this data in an accessible and reliable format.

Altmetric is supported by Digital Science – a technology company that combines world-class technology with a resolute focus on scientists and those who support the research process. Find out more at altmetric.com and follow us on Twitter @altmetric.

Digital Science is a technology company serving the needs of scientific and research communities, at the laboratory bench or in a research setting. It invests in and incubates scientific software companies that simplify the research cycle, making more time for discovery. Its portfolio companies and investments include a host of leading and admired brands including Altmetric, BioRAFT, Figshare, GRID, Labguru, Peerwith, Overleaf, ReadCube, Symplectic, TetraScience, Transcriptic, and ÜberResearch. It is operated by global media company, the Holtzbrinck Publishing Group. Visit http://www.digital-science.com and follow @digitalsci on Twitter.

Close

Envision Pharma Group launches Medinfo™ – a new purpose-built software solution for medical information

Mar 20, 2017
Envision Pharma Group launches Medinfo™ – a new purpose-built software solution for medical information Image

Medinfo is a complete, globally scalable solution that transparently and compliantly manages the provision of medical information to healthcare professionals, patients, caregivers, and other enquirers. Medinfo is currently being implemented at several companies.

Medinfo is built on the iEnvision™ platform and is part of the integrated suite of iEnvision solutions, purpose-built to meet the needs of Medical Affairs and related functions. Medinfo can be fully integrated with other iEnvision solutions such as Datavision® (publications management), Library™ (scientific content asset management), and Clear® (system-managed clearance and approval processing), as well as other third-party and corporate applications including CRM, other CMS, pharmacovigilance, and product quality systems.

Validation, audit, and transparency reporting requirements are a key aspect, with standard Medinfo implementations being validated to Software Validation Process 21 CFR Part 11 Compliant GxP Standards. Further client-configured validation support is available.

Medinfo was developed in-house at Envision as a specific medical information solution under the guidance of a team of senior medical information specialists with over 35 years cumulative experience in hands-on, industry-based medical information roles. This was combined with Envision’s 15-year experience in providing medical request- and scientific communications-related technology solutions to create a robust, advanced, and purpose-specific solution for medical information needs.

Medinfo provides a next generation medical information solution comprising multichannel request intake using an integrated web portal, streamlined and simplified enquiry management processing with adverse event and product quality intake capabilities, system-suggested response generation support, and robust content creation and management facilities. Built-in analytical features including dashboards, metrics, and reporting enable insights to be captured, this in turn, can inform and improve response quality, as well as future data and evidence generation requirements. Medinfo quickly and efficiently helps get the right answer to the enquirer and enables actionable insights to improve future responses. In addition, the Operational Excellence Consulting arm of Envision is able to provide complementary standard response medical writing and implementation support services.

For further information, please contact: Kelli Walker (kelli.walker@EnvisionPharmaGroup.com) or Russell Traynor (Russell.Traynor@EnvisionPharmaGroup.com).

About Envision

Founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies.

Envision is a leading provider of evidence communication services and industry-leading, technology solutions that have applicability across areas of Medical Affairs responsibility.

Under consistent leadership, Envision has grown steadily across its three core business areas in support of Medical Affairs:

(i) Evidence Communication—including strategic publication planning, data dissemination services, medical education, and Market Access communications;

(ii) Technology Solutions—design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including: publication planning and management (Datavision®), clearance and approval (Clear®), activity request and evidence generation management (Visiontracker®), workflow management for Health Economics and Outcomes Research activities (Visiontracker HEOR™), workflow management for Early Access Program activities (Visiontracker EAP™), searchable repository for the appropriate sharing of scientific content (Library), and a next-generation solution for managing medical information enquiries (Medinfo™); and

(iii) Operational Excellence—policy, process, and compliance support and consultancy for Medical Affairs.

Envision has 12 offices: four in the United Kingdom – Horsham, Wilmslow, Marlow, and London; six in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT, and New York, NY; and two in the Asia-Pacific region – Tokyo and Sydney. The company employs 520 team members, including more than 200 highly qualified and experienced in-house medical writers and more than 100 technology solutions team members who provide software development and customer support. Envision provides services and technology solutions to more than 75 companies, including 19 of the top 20 pharmaceutical companies.

Close

Envision Pharma Group acquires Curo Consulting Ltd

Envision Pharma Group (“Envision”), a leading Medical Affairs-focused scientific communications and technology solutions provider, has acquired Curo Consulting Ltd

Market Access - Envision Pharma Group presented original research at ISPOR in Boston, May 20–24

Envision Pharma Group presented original research at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – Sheraton Boston Hotel and the John B. Hynes Veterans Memorial Convention Center, Boston, MA, USA, May 20−24, 2017

Envision Pharma Group – new leadership positions

Envision Pharma Group (“Envision”), a highly successful Medical Affairs-focused, technology-enabled scientific communications company is delighted to announce two new roles within our leadership team

Envision Pharma Group acquires Curo Consulting Ltd

Jan 26, 2017
Envision Pharma Group acquires Curo Consulting Ltd Image

Curo specializes in enabling biopharma companies to communicate with payers, policy makers, and providers ‘in their language’ and notably, Curo won the Queen’s Award for Enterprise – International Trade in 2015, the UK’s highest accolade for business success. Curo’s Chairman, Jonathan Mowll, and CEO, Christopher O’Neill, will continue to drive Curo’s operations and will join Envision’s management team.

The acquisition was supported by Envision’s equity partners – Ardian, the independent private investment company, and GHO Capital, the specialist European investor in healthcare. Additional terms of the transaction were not disclosed.

Operating globally, Envision is a leading partner to Medical Affairs organizations, providing scientific data communication services and industry standard technology solutions to biopharmaceutical and medical device companies.

Envision’s unique position within the growing market of outsourced Medical Affairs services, including value-oriented communications, is underpinned by integrating scientific and industry expertise with a range of purpose-built technology solutions that facilitate planning, knowledge-sharing, operational excellence, and decision-making.

Curo’s core skill set in creating effective Market Access strategies, delivered in an innovative and compelling manner, will bolster Envision’s existing Market Access solutions and complement the group’s wider range of services – including medical writing, publication planning, medical communications, and operational excellence consultancy.

Similarly, Curo’s HEOR and Market Access software will complement Envision’s extensive range of industry-leading technology solutions (Datavision®, Library™, Visiontracker®, Clear®, Medinfo™ and Visiontracker HEOR™). Curo’s state-of-the-art applications – LENS™, which dynamically matches key data sets with payer needs, and Evidence Navigator™, which facilitates value narratives tailored to the needs of different payer archetypes – will be valuable additions to Envision’s range of technology solutions and provide an essential toolkit for our Market Access clients.

Envision's CEO, Brian Hepburn, commented, "The addition of Curo to the Envision Pharma Group augments our existing Market Access capabilities and further cements our core tenet of marrying expertise and technology to become the leading international Medical Affairs agency. In the current biopharma landscape, value demonstration is an essential part of the evidence communication package. Curo’s consulting expertise and software products will ensure that we offer optimal evidence communication strategies to our clients.”

Curo CEO, Christopher O’Neill, stated, “We are absolutely delighted to become part of Envision. Curo has spent the past 3 years building and proving the impact of a series of innovative digital platforms to support Value Curation in HEOR and Market Access. In Envision, we have found a partner with the same commitment to combining services with supporting technology. Philosophically, this is incredibly important. Practically, the size and reach of the Envision group will give us the opportunity to build out a scalable infrastructure which will enable us to service our clients with more comprehensive end-to-end Value Curation solutions.”

About Envision

Founded in 2001, Envision Pharma is an international, innovative global technology and scientific communication company serving pharmaceutical, biotechnology, and medical device companies. Initially focusing on re-inventing the way biopharma companies managed their global data communications programs through the use of smart technology and best-in-class publication planning, Envision has evolved to become a leading provider of evidence communication services and Medical Affairs solutions encompassing all aspects of scientifically driven data dissemination activities required to support a successful access to market strategy for new biopharma compounds.

This capability of the organization is further enhanced with industry-leading, complementary technology solutions across the Medical Affairs responsibilities. Envision has grown steadily under consistent leadership across its three core business areas in support of the Medical Affairs team that include (i) Evidence Communication – including strategic publication planning, data dissemination services, medical education, and Market Access communications; (ii) Technology Solutions – design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including, publication planning and management (Datavision®), clearance approval (Clear®), activity request management (Visiontracker®), workflow management for HEOR activities (Visiontracker HEORTM), searchable repository for the sharing of appropriate educational and training materials (LibraryTM), and next-generation solution for managing medical information enquiries (MedinfoTM); (iii) Consulting Solutions – policy, process, compliance, and guideline consultancy to life-science companies.

Envision currently has ten offices, three in the United Kingdom – Horsham, Wilmslow, and London; five in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT; and two in Asia Pacific – Tokyo and Sydney. The company employs approximately 500 team members, including over 200 highly qualified and experienced in-house medical writers and a more than 80-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 18 of the top 20 pharmaceutical companies.

About Curo

With over a decade’s experience in the wider consulting industry, Curo offers a new perspective and a different approach to Market Access. Well respected in the industry, we pride ourselves on thinking beyond the usual parameters of the pharma world. True, we have a team of Health Economics experts and specialist software builders, but we are not data processors, nor a software company. Instead, we use our resources to build narratives that speak to Payers and answer their questions; helping you to show that it is value that matters, not cost. Curo are also proud winners of The Queen’s Award for Enterprise – International Trade, 2015, the UK’s highest accolade for business success.

About Ardian

Ardian, founded in 1996 and led by Dominique Senequier, is an independent private investment company with assets of US$55bn managed or advised in Europe, North America, or Asia. The company, which is majority-owned by its employees, keeps entrepreneurship at its heart and delivers investment performance to its global investors while fuelling growth in economies across the world. Ardian’s investment process embodies three values: excellence, loyalty, and entrepreneurship.

Ardian maintains a truly global network, with more than 410 employees working through twelve offices in Paris, London, Frankfurt, Milan, Madrid, Zurich, New York, San Francisco, Beijing, Singapore, Jersey, and Luxembourg. The company offers its 470 investors a diversified choice of funds covering the full range of asset classes through Ardian Direct Funds (comprising Ardian Mid Cap Buyout, Ardian Expansion, Ardian Growth, and Ardian Co-Investment), Ardian Infrastructure, Ardian Funds of Funds (comprising primary, early secondary, and secondary activities), Ardian Private Debt, Ardian Real Estate, and customized mandate investment solutions with Ardian Mandates.

About GHO Capital

Global Healthcare Opportunities, or GHO Capital Partners LLP, was founded in 2014 as a specialist healthcare investment adviser based in London. Its vision is to apply global capabilities and perspectives to build a world-class healthcare specialist private equity firm by recognising and seizing the highly attractive and underpenetrated European market opportunity. GHO Capital has a powerful combination of transaction, investment, and industry skills which sets it apart from traditional private equity firms. For further information, please visit www.ghocapital.com.

Contact: Trevor Fitzpatrick - Trevor.Fitzpatrick@EnvisionPharmaGroup.com

Close

Market Access - Envision Pharma Group presented original research at ISPOR in Boston, May 20–24

Oct 26, 2016
Market Access - Envision Pharma Group presented original research at ISPOR in Boston, May 20–24 Image

Members of Envision’s Market Access Solutions team and their co-authors presented new insights on the important issue of biosimilar uptake and use in the USA.

Both presentations took place in Research Poster Presentations – Session II was on Monday, May 22nd (3:45-7:45pm), with an Author Discussion Hour between 6:45pm and 7:45pm.

Envision’s Karen Smoyer, PhD and Bríain Ó Hartaigh, PhD presented research on the “Uptake of the First US Biosimilar: Filgrastim-sndz Utilization Observed in a Medical Transcription Database of Patient Office Visits”.

Envision’s Karen Smoyer, PhD and Trevor Fitzpatrick, CMPP presented research conducted in collaboration with Cardinal Health on the “Initial Uptake and Utilization Patterns of Filgrastim-sndz, the First US Biosimilar”.

The theme of this year’s meeting was “Evidence and Value in a Time of Social and Policy Change” and full details of the agenda can be found here or via the meeting App for iOS or ANDROID devices.

Events were followed in Boston on Twitter using #ISPORBoston

Close

Envision Pharma Group – new leadership positions

Oct 10, 2016
Envision Pharma Group – new leadership positions Image

Dr Joseph Kohles will assume the position of Chief Medical Officer (CMO) to provide medical leadership across the group, provide direction for the development of medical strategy for our clients, provide a peer-to-peer contact for our Medical Affairs clients, and aid in the development/optimization of new technology solutions to support our expanding range of Medical Affairs services. Joe will also head-up a Medical Strategy “think tank” within Envision to provide our clients with leading-edge solutions to the changing demands of the Medical Affairs team and the environment in which they operate.

David Thompson will assume the position of Chief Strategy Officer (CSO) to help drive Envision's continued growth into the leading, global Medical Affairs agency, incorporating expanded multichannel medical communications capabilities, and oversee our expansion into appropriate global locations to facilitate closer proximity to our client base. David will also ensure the continued and improved synergy between our scientific services and supporting technology solutions to maintain Envision’s position as the only medical communications company that encompasses world-class scientific expertise, supported by industry-leading technology solutions to compliantly deliver multichannel medical communication programs. Although responsible for ensuring effective delivery of our scientific services across all 10 of our current global offices, David will be relocating to the UK as part of his new role, and will be based out of our Horsham office for alignment with the existing operational leadership team.

The current leadership team Brian Hepburn (CEO), Greg Caswill (Chairman), Joe Brown (President of Envision Technology Solutions) and John Gillie (CFO) will remain in their existing positions and welcome the augmented structure of leadership team as Envision continue their expansion.

Brian Hepburn, commented, “David and Joe bring incremental strength and depth to the management team, further extending our capabilities and expertise and enhancing our objective of becoming the comprehensive strategic partner to the Medical Affairs departments of our extensive client base.”

Envision Pharma Group are still recruiting for open positions at all levels across the organization – https://www.envisionpharmagroup.com/careers.

For an informal discussion, or to apply for any of these roles, please contact Karen Kent (Envision Pharma Group Recruiter – Karen.Kent@EnvisionPharmaGroup.com).

About Envision

Founded in 2001, Envision Pharma Group is an international, innovative global technology and scientific communication company serving pharmaceutical, biotechnology, and medical device companies. Initially focusing on re-inventing the way biopharma companies managed their global data communications programs through the use of smart technology and best-in-class publication planning; Envision has evolved to become a leading provider of evidence communication services and Medical Affairs solutions encompassing all aspects of scientifically-driven data dissemination activities required to support a successful access to market strategy for new biopharma compounds.

This capability of the organization is further enhanced with industry-leading, complementary technology solutions across the Medical Affairs responsibilities. Envision has grown steadily under consistent leadership across its three core business areas in support of the Medical Affairs team that include (i) Evidence Communication – including strategic publication planning, data dissemination services, medical education, and Market Access communications; (ii) Technology Solutions – design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including, publication planning and management (Datavision®), clearance approval (Clear®), activity request management (Visiontracker®), workflow management for HEOR activities (Visiontracker HEORTM), searchable repository for the sharing of appropriate educational and training materials (LibraryTM), and next generation solution for managing medical information enquiries (MedinfoTM); (iii) Consulting Solutions – policy, process, compliance, and guideline consultancy to life-science companies.

Envision currently has ten offices, three in the United Kingdom – Horsham, Wilmslow, and London; five in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT; and two in Asia Pacific – Tokyo and Sydney. The company employs approximately 450 team members, including over 185 highly qualified and experienced in-house medical writers and a more than 80-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 18 of the top 20 pharmaceutical companies.

Close